Objective: To identify and analyse factors underlying intern prescribing errors to inform development of specific medication‐safety interventions. Design: A prospective qualitative study that involved face‐to‐face interviews and human‐factor analysis. Setting: A tertiary referral teaching hospital, Brisbane, Queensland, February–June, 2004. Participants: Fourteen intern prescribers involved in 21 errors. Method: A structured questionnaire was used to identify factors causing the errors. Transcripts were analysed on the basis of human‐error theory to identify underlying themes. Main outcome measures: Factors underlying prescribing errors. Results: Errors were multifactorial, with a median of 4 (range, 2–5) different types of performance‐influencing factors per error. Lack of drug knowledge was not the single causative factor in any incident. The factors in new‐prescribing errors included team, individual, patient and task factors. Factors associated with errors in represcribing were environment, task and number of weeks into the term. Defences against error, such as other clinicians and guidelines, were porous, and supervision was inadequate or not tailored to the patient, task, intern or environment. Factors were underpinned by an underlying culture in which prescribing is seen as a repetitive low‐risk chore. Conclusion: To reduce the risk of prescribing errors, a range of strategies addressing patient, task, individual, team and environment factors must be introduced.

No abstract

Minimising the harm from inappropriate prescribing in older populations is a major urgent concern for modern healthcare systems. In everyday encounters between prescribers and patients, opportunities should be taken to identify patients at high risk of harm from polypharmacy and reappraise their need for specific drugs. Attempts to reconcile life expectancy, comorbidity burden, care goals and patient preferences with the benefits and harms of medications should be made in every patient at significant risk. Drugs identified by this process of reconciliation as conferring little or no benefit and/or excessive risk of harm should be candidates for discontinuation. Evidence supporting a structured approach to drug discontinuation (or deprescribing) is emerging, and while many barriers to deprescribing exist in routine practice, various enabling strategies can help overcome them.